Aptose Biosciences Company Overview
Aptose Biosciences
About Aptose Biosciences
Aptose Biosciences (TSX:APS), (NASDAQ:APTO) is a biotechnology firm focused on developing personalized therapies to address unmet medical needs in oncology, particularly in the treatment of life-threatening cancers. Aptose Biosciences operates with a keen eye on innovative research to advance the development of its pipeline products, which are designed to target the underlying mechanisms of cancer. The company is dedicated to pushing the boundaries of science to bring forward novel treatments that can offer better outcomes for patients battling cancer. Their objectives revolve around progressing their clinical trials, securing strategic partnerships, and advancing their research to bring transformative cancer therapies to the market.
What is Aptose Biosciences known for?
Snapshot
1986
Year founded
36
Employees
Toronto, Canada
Head office
Loading Map...
Operations
All Locations
Toronto, CA
Produtos e/ou serviços de Aptose Biosciences
- Luxeptinib, a dual FLT3 and BTK inhibitor for acute myeloid leukemia and B-cell malignancies.
- APTO-253, induces expression of the KLF4 gene, targeting acute myeloid leukemia and myelodysplastic syndromes.
- Preclinical BTK inhibitors program targeting B-cell malignancies with a focus on overcoming resistance.
- Preclinical FLT3 inhibitors program tailored for acute myeloid leukemia with a goal to evade current treatment resistance.
- Collaborations with major pharmaceutical firms to enhance research, development, and commercialization of novel therapeutics.
equipe executiva do Aptose Biosciences
- Dr. William G. Rice Ph.D.Chairman, President & CEO
- Mr. Fletcher PayneSenior VP, CFO, Chief Business Officer & Secretary
- Dr. Rafael Bejar M.D., Ph.D.Senior VP & Chief Medical Officer
- Dr. Marc Wiles Ph.D.Senior Vice President of Regulatory Affairs